FDA-CLEARED DIGNICAP® SCALP COOLING SYSTEM IS NOW AVAILABLE FOR WOMEN WITH BREAST CANCER AT 10 U.S. CANCER TREATMENT CENTERS

First and Only FDA Cleared Scalp Cooling Device To Reduce Chemotherapy Related
Hair Loss Provides an Alternative to One of the Most Devastating Side Effects
Feared by Patients with Breast Cancer
Dallas, TX—March 29, 2016—Dignitana Inc., a world leader in medical scalp
-cooling technology, announced today that the DigniCap® scalp cooling system,
which was cleared by the FDA in December to effectively reduce the likelihood of
chemotherapy-induced hair loss in women with breast cancer, is now available at
ten cancer treatment centers across the United States. Scalp cooling is
administered alongside chemotherapy in medical infusion centers.

The DigniCap® system is the first and only scalp cooling device to complete
rigorous FDA clinical trials in the U.S., where seven out of 10 patients with
early-stage breast cancer kept at least 50% of their hair.

The DigniCap® scalp cooling system features a patented tight-fitting silicone
cooling cap that is placed directly on the head, and an outer neoprene cap that
insulates and secures the silicone cap. The cooling cap is connected to a
cooling and control unit with touch screen prompts. A liquid coolant circulates
throughout the silicone cap, delivering consistent and controlled cooling to all
areas of the scalp. The cap is fitted to the head, and the temperature of the
scalp is lowered, resulting in vasoconstriction with reduced delivery of
chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to
decreased intra follicular metabolic rate. These factors together reduce the
risk of chemotherapy-induced hair loss.

The following cancer treatment centers will be the first 10 sites in the U.S. to
provide the DigniCap® scalp cooling system in their breast cancer treatment
regimens:

  · Charleston Hematology Oncology Associates (https://www.choasc.com/)
Charleston, South Carolina
  · Chesapeake Oncology and Hematology Associates (http://cohamed.org/)
Glen Burnie, Maryland
  · Florida Cancer Specialists & Research Institute (https://www.flcancer.com/)
Sarasota, Florida
  · Mount Sinai Comprehensive Cancer Center (http://msccc.com/)
Miami Beach, Florida
  · Orange County Blood and Cancer Care (http://www.memorialcare.org/)
Fountain Valley, California
  · The Angeles Clinic and Research Institute, an affilliate of Cedars
-Sinai (http://www.theangelesclinic.org/)
Los Angeles, California
  · Toledo Clinic Cancer Center (http://www.toledocliniccancercenters.com/)
Toledo, Ohio
  · UCSF Helen Diller Family Comprehensive Cancer
Center (http://cancer.ucsf.edu/)
San Francisco, California
  · UT Health Science Center San Antonio’s Cancer Therapy & Research
Center (http://www.uthscsa.edu/patient-care/ctrc)
San Antonio, Texas
  · Wake Forest Baptist Medical Center (http://www.wakehealth.edu/)
Winston Salem, North Carolina

Wake Forest Baptist Medical Center in North Carolina was the first medical
center in the United States to sign an agreement with Dignitana in order to
offer the DigniCap® system to patients undergoing chemotherapy for breast
cancer, while UT Health Science Center’s Cancer Therapy & Research Center in San
Antonio was first to actually use the device for treatment. Dr. Hope Rugo at
UCSF’s Helen Diller Family Comprehensive Cancer Center, principal investigator
for the FDA multi-center clinical trial, and Dr. Susan Melin at Wake Forest
Baptist, principal investigator for the trial there, originated early clinical
trials and shepherded studies throughout the FDA process.

“We are proud to have helped bring this new treatment option to women in the
U.S.,” says Dr. Hope S. Rugo, Principal Investigator for the study and Director
of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family
Comprehensive Cancer Center. “A breast cancer diagnosis is traumatizing enough,
there’s no need to add fear of hair loss to the experience.”

"We are very excited to be the first oncology practice in the area to provide
the DigniCap system to our breast cancer patients. Losing hair during
chemotherapy can be a devastating experience and no woman should have to go
through such physical and emotional trauma in this day and age,” comments Dr.
Young Lee from Chesapeake Oncology & Hematology COHA. “In the past, we have used
different types of scalp cooling caps that were very cumbersome and labor
intensive. DigniCap makes the process so much easier and is truly a breakthrough
technology that will forever change the lives of breast cancer patients. Cancer
will no longer take your hair and your identity away. You are in control. No
more stigma!"

“The availability of DigniCap to improve the quality of life and enhance the
self-image of patients undergoing chemotherapy provides a tremendous boost to
cancer patients and their families,” said Dr. Cathie Chung, a
hematology/oncology physician at The Angeles Clinic and Research Institute, an
affiliate of Cedars-Sinai. “It’s about time that we have a safe, effective and
comfortable way to prevent chemotherapy–induced alopecia, as this can be the
most devastating side effect of therapy for many patients.“

“We are very excited about this first group of 10 sites offering the DigniCap
scalp cooling system to their patients. They represent an excellent cross
section of the oncology industry and range from large research hospitals to
specialty community practices,” said Bill Cronin, COO of Dignitana, Inc., which
is headquartered in Dallas, Texas. “We are grateful for the opportunity to work
with these facilities and all of those we will be bringing on across the country
to begin the process of helping women deal with this most unfortunate side
effect of chemotherapy.”

To learn more about the DigniCap® scalp cooling system please contact one of the
treatment centers or visit www.DigniCap.com.
Media Contact:

Cynthia
Inacio


King
Company


00 1 212 561
-7464


Cynthia.inacio@kingcompr.com (Caren.Browning@kingcompr.com)

About Dignitana, Inc.
Headquartered in Dallas, Texas, Dignitana, Inc. is the U.S.
subsidiary of Dignitana AB, a Swedish public company, based in Lund, and
manufacturer of the patented DigniCap® system medical scalp cooling
device. Dignitana is continuously researching and developing new uses for
DigniCap® technology. Dignitana AB is listed on the OMX Nasdaq First North stock
exchange and has appointed Erik Penser Bankaktiebolag as Certified Advisor. For
more information visit www.DigniCap.com.

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that
offers cancer patients the ability to keep their hair during chemotherapy.
DigniCap® is developed to provide continuous cooling with high efficacy, safety
and acceptable patient comfort.